Purpose. The absorption potential and metabolism of 8-prenylnaringenin (8-PN) from hops (Humulus lupulus L.) were investigated. 8-PN is a potent estrogen with the potential to be used for the relief of menopausal symptoms in women. Methods. Monolayers of the human intestinal epithelial cancer cell line Caco-2 and human hepatocytes were incubated with 8-PN to model its intestinal absorption and hepatic metabolism, respectively. Results. The apparent permeability coefficients for 8-PN in the apical-to-basolateral and basolateral-toapical directions of a Caco-2 monolayer were 5.2 T 0.7 Â 10 j5 and 4.9 T 0.5 Â 10 j5 cm/s, respectively, indicating good intestinal absorption via passive diffusion. Both glucuronide and sulfate conjugates of 8-PN were detected in the Caco-2 cell incubations. The 4 0 -O-glucuronide was the predominant Caco-2 cell metabolite, followed by 7-O-sulfate and 4 0 -O-sulfate. Both phase I and phase II metabolites of 8-PN were formed by human hepatocytes. The 7-O-glucuronide was the most abundant hepatocyte metabolite, and no sulfate conjugates were detected. Incubations with various cDNA-expressed UDPglucuronosyltransferases indicated that the isozymes UGT1A1, UGT1A6, UGT1A8, and UGT1A9 were responsible for glucuronidation of 8-PN. Conclusions. Although orally administered 8-PN should be readily absorbed from the intestine, its bioavailability should be reduced significantly by intestinal and hepatic metabolism.
INTRODUCTION
The female flowers of hops (Humulus lupulus L.) are used in the brewing industry as a flavoring agent for beer. Recently, there has been interest in the potential estrogenic activities of hop extracts. Based on anecdotal reports of menstrual disturbances among women who pick hops in Germany, menopausal women sometimes take hops baths to seek relief from hot flashes (1) . In addition, hops extracts have become major constituents of an increasing number of commercial preparations marketed for breast enhancement (2) .
Among the possible active constituents, the flavonoid 8-prenylnaringenin (8-PN; see structure in Fig. 1 ) has attracted the most attention. 8-PN belongs to the group of prenylated flavanones, which includes isoxanthohumol, 6-prenylnaringenin, and a number of diprenylated analogs (3) . Various in vitro studies have identified 8-PN as one of the most potent estrogens in hops with a potency equal to or greater than other established plant estrogens such as genistein or coumestrol (1, 4, 5) . Milligan et al. (6) showed that 8-PN is estrogenic in rats in vivo, although its activity seemed to be much weaker than that of estradiol.
Few data exist in the literature concerning the metabolism or bioavailability of 8-PN or other prenylated flavonoids. Yilmazer et al. (7, 8) studied rat liver microsomal metabolism of xanthohumol and identified four phase I metabolites and two phase II glucuronides. We have identified several phase I metabolites of 8-PN formed by human liver microsomes (9) . In the present study, we investigated the intestinal permeability and metabolism of 8-PN using human Caco-2 cell monolayers as a model system for intestinal absorption and metabolism. In addition, incubation of 8-PN with human hepatocytes was used as a model for liver metabolism.
Together, these two models provided important predictive information regarding the oral bioavailability of 8-PN.
MATERIALS AND METHODS

Chemicals
Racemic 8-PN was isolated from a methanolic extract of spent Nugget hops (Humulus lupulus cv. Nugget, plant material previously extracted with supercritical carbon dioxide) and purified by semipreparative high-performance liquid chromatography (HPLC). Purity was determined to be >98% based on HPLC and liquid chromatographyYmass spectrometry (LCYMS) analyses. Uridine diphosphoglucuronic acid, mannitol, propranolol, naringenin, b-glucuronidase (type B-10 from bovine liver), and sulfatase (type VI, from Aerobacter aerogenes, partially purified) were purchased from Sigma-Aldrich (St. Louis, MO, USA). MK571 was purchased from Cayman Chemical (Ann Arbor, MI, USA). All organic solvents were HPLC-grade and were purchased from Fisher Scientific (Fair Lawn, NY, USA).
The Caco-2 cell line (originating from a human colorectal carcinoma), Eagle's minimum essential medium, and fetal bovine serum were purchased from the American Type Culture Collection (Rockville, MD, USA). TrypsinYEDTA (0.25%), Hank's balanced salt solution (HBSS), penicillin, and streptomycin were purchased from Life Technology (Grand Island, NY, USA). Six-well cell culture plates with polycarbonate inserts (24.4 mm in diameter, 4.71 cm 2 surface area, and 3.0 mm pore size) were purchased from Corning Costar (Cambridge, MA, USA). The Millicell-ERS instrument used for measuring the transepithelial electrical resistance (TEER) of the Caco-2 cell monolayers was obtained from Millipore (Bedford, MA, USA). Cryopreserved human hepatocytes were purchased from In Vitro Technologies (Baltimore, MD, USA) and were handled according to the supplier's instructions. cDNA-expressed uridine diphosphoglucuronosyltransferases (UGTs), prepared from baculovirus-infected insect cells (SUPERSOMESi), were purchased from Gentest (Woburn, MA, USA).
Cell Culture
Caco-2 cells were cultured at 37-C in an atmosphere of 5% CO 2 and 90% relative humidity in Eagle's minimum essential medium with 10% fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin. Confluent monolayers were subcultured every 7 days by treatment with 0.25% trypsin containing EDTA. For transport and metabolism studies, Caco-2 cells (passage numbers 20Y35) were seeded onto polycarbonate membranes at a density of 2 Â 10 5 cells per insert and grown to late confluence (15Y21 days). and human hepatocytes. Note that S1 and S2 are sulfate conjugates and that G1YG8 are glucuronides.
The culture medium was changed every other day after seeding. The integrity of the monolayers of the differentiated Caco-2 cells was monitored by measuring the TEER value, and only monolayers with values >300 WIcm 2 were used.
Measurement of Apparent Permeability Coefficients
After the complete culture medium was removed from both the apical (AP) and basolateral (BL) chambers, the monolayers were washed three times and then preincubated with HBSS at pH 7.4 for 30 min at 37-C on a shaker bath at 50 rpm. 8-PN was added to either the apical chambers (for AP Y BL permeability measurements) or the basolateral chambers (for BL Y AP studies) at an initial concentration of 50 mM in HBSS. The concentration of 50 mM was selected because it is a biologically relevant concentration of 8-PN that might occur in the intestinal lumen following oral administration of 8-PN or hops preparations enriched in 8-PN. As a marker of paracellular transport, mannitol (50 mM final concentration) was added to each apical chamber. In separate Caco-2 control experiments, propranolol was added to the apical chamber at 10 mM and assayed as described above for 8-PN as an example of a high-permeability compound. The volumes of the solutions in the apical and basolateral chambers were 1.5 and 2.6 mL, respectively.
At the time points 5, 10, 20, 40, or 60 min, solutions in the recipient compartments of the incubations described above were removed and replaced with fresh medium. The samples were stored at j20-C until analysis for 8-PN using LCYMS. These samples were analyzed for 8-PN, mannitol, and, in some experiments, propranolol. The apparent permeability coefficients (P app ) expressed in centimeters per second were calculated using the following equation: P app = V R Â dC/dt Â 1/AC 0 . V R is the volume of the recipient compartment (2.6 and 1.5 mL for basolateral and apical compartments, respectively); dC/dt is the slope of the cumulative concentration (micromolar) of 8-PN in the recipient chamber over time (seconds); A is the membrane surface area (4.71 cm 2 ); and C 0 is the initial concentration of 8-PN in the donor chamber (micromolar). The apparent permeability coefficients were obtained under Bsink conditions,^i.e., less than 10% transported, to minimize diffusion of the solute back from the receiving to the donor compartment. All experiments were carried out in triplicate.
During the Caco-2 permeability studies, the TEER values of the Caco-2 cell monolayers measured before and after the 1-h incubations were determined to be identical at 554 T 12 and 542 T 14 WIcm 2 , respectively. As a low-permeability control, the apparent permeability coefficient of mannitol was measured in the apical-to-basolateral direction and was acceptably low at 0.32 (T0.02) Â 10 j6 cm/s (N = 3). In addition, the apparent permeability coefficient of the highpermeability standard propranolol was determined in the apical-to-basolateral direction and was appropriately high at 5.4 (T0.4) Â 10 j5 cm/s (N = 3). These experiments verified the integrity of the Caco-2 cell monolayers and helped calibrate the assay.
Caco-2 Cell Metabolism of 8-PN
A 1.5-mL aliquot of a 50-mM 8-PN solution (in HBSS) was added to either the apical or basolateral chambers of the Caco-2 cell monolayers. After 4 h of incubation, both apical and basolateral solutions were collected for LCYMS analysis of 8-PN and its metabolites. To determine the possible role of ABCC2 (MRP2) in the transport of 8-PN phase II conjugates, 8-PN was incubated with Caco-2 cells for 4 h exactly as described above except that the ABCC2 (MRP2) inhibitor MK571 (50 mM) was included to both the apical and basolateral chambers. These experiments were carried out in duplicate. The chemical stability of 8-PN in HBSS at 37-C was examined under the same conditions as in the metabolism study but without the Caco-2 cell monolayers. The TEER values of the Caco-2 cell monolayers were measured before and after the 4-h incubations to ensure monolayer integrity.
Metabolism of 8-PN by Human Hepatocytes
Cryopreserved hepatocytes were thawed according to the supplier's instructions, and approximately 1 Â 10 6 cells in a 1-mL suspension were incubated with 8-PN (10-mL aliquot of a 5 mM solution in dimethyl sulfoxide) per well of a 12-well plate. Control experiments were identical except for the substitution with heat-inactivated hepatocytes. The plate was placed in an incubator at 37-C with 5% CO 2 and 90% relative humidity and gently shaken at 50 rpm for 4 h. Incubations were terminated by the addition of 3 mL of icecold methanol. The cell suspensions were centrifuged, and aliquots of the supernatants were analyzed using LCYMS and LCYMSYMS.
Glucuronidation by cDNA-Expressed UDP-Glucuronosyltransferases
Incubations with human recombinant UGT1A1, UGT1A6, UGT1A8, UGT1A9, UGT1A10, and UGT2B7 were carried out according to the protocol recommended by the supplier (Gentest) with the modifications of Fisher et al. (10) . Briefly, 0.04 mg of the protein preparation was mixed with 2 mg alamethicin and 148 mL of 50 mM phosphate buffer (pH 7.4) and placed on ice for 15 min. Next, magnesium chloride (10 mM final concentration) and 8-PN (50 mM final concentration, added in 2 ml of methanol) were added, and the mixture was preincubated for 3 min at 37-C. Reactions were initiated by adding uridine diphosphoglucuronic acid (2 mM final concentration in a total volume of 0.2 mL), and incubations were carried out for 30 min. The reactions were terminated by the addition of 100 mL of acetonitrile/acetic acid (94:6, v/v), and each sample was centrifuged at 10,000 Â g for 3 min. Finally, 10-mL aliquots of each supernatant were analyzed using LCYMS or LCYMSYMS.
LCYUVYMS and LCYMSYMS
Mass spectrometric analyses were carried out using a Waters (Milford, MA, USA) 2690 HPLC system interfaced to a Micromass (Manchester, UK) Q-TOF-2 hybrid quadrupoletime-of-flight mass spectrometer equipped with electrospray ionization. HPLC separations of 8-PN and its metabolites were carried out using a YMC (Wilmington, NC, USA) AQ 2.1 Â 250 or 2.1 Â 150 mm C 18 column with a binary gradient solvent system consisting of 0.05% acetic acid in water (solvent A) and methanol (solvent B). The gradient program consisted of 45% B for 10 min, a linear gradient from 45 to 68% B over 35 min, 68% B for another 5 min, a linear gradient from 68 to 90% B over the next 10 min, 90% B for 10 min, and finally returning to 45% B in 2 min. The flow rate was 0.2 mL/min.
Although negative ion electrospray provided the greatest signal-to-noise for metabolites of 8-PN, positive ion electrospray tandem mass spectrometry was also used to obtain complementary structural information for the metabolites. For most measurements, mass spectra were obtained at a resolving power of 5000 full width at half maximum (FWHM) at m/z 500. However, the resolving power was increased to 8000 FWHM at m/z 500 for exact mass measurements. Polyethylene glycol was used for calibration, and raffinose ([M-H] j , m/z 503.1612) was added postcolumn as a lock mass for exact mass measurements. Data were acquired from m/z 250 to 900. Product ion tandem mass spectra were acquired using collision-induced dissociation (CID) with argon at a collision energy of 25 eV. UV spectra were obtained during LCYUVYMS over the range 190Y370 nm using a photodiode array absorbance detector.
Propranolol and mannitol concentrations in the basolateral chambers were determined using an Agilent (Palo Alto, CA, USA) G1946A single quadrupole mass spectrometer with an 1100 HPLC system. Positive ion electrospray was used with selected ion monitoring to measure the protonated molecule of propranolol at m/z 260 and the protonated internal standard acebutolol at m/z 337. The internal standard was added immediately before LCYMS analysis to control for variations in sample handling and LCYMS response. HPLC separation of propranolol and acebutolol was carried out using a reversed-phase Waters Xterra C 18 column (2.1 Â 100 mm, 3.5 mm). The mobile phase consisted of an 8-min linear gradient from 15:85 to 50:50 0.5% acetic acid/methanol (v/v) followed by a 3-min hold before returning to the initial mobile phase composition at a flow rate of 0.2 mL/min. The retention times of propranolol and the internal standard were 9.2 and 3.6 min, respectively. For the analysis of mannitol, negative ion electrospray and selected ion monitoring were used to record the signal for the deprotonated molecule of mannitol at m/z 181 as it eluted from a YMC NH 2 column (2.0 Â 150 mm, 5 mM). The mobile phase for the mannitol LCYMS analysis consisted of a 10-min linear gradient from 10:90 to 16:84 water/acetonitrile (v/v) at a flow rate of 0.5 mL/min. Mannitol eluted at 6.6 min under these HPLC conditions. Standard curves were prepared for the LCYMS measurement of mannitol and propranolol in HBSS.
RESULTS
Permeation of the Caco-2 Monolayer
The human intestinal permeability of 8-PN was evaluated using the Caco-2 cell monolayer model system. Under the conditions of these experiments, the rate of 8-PN movement across the monolayer was linear for up to 1 h. The apparent permeability coefficients P app of 8-PN in the apical-to-basolateral (AP Y BL) and basolateral-to-apical (BL Y AP) directions were 5.2 T 0.7 Â 10 j5 and 4.9 T 0.5 Â 10 j5 cm/s, respectively. These values are similar to those of drugs such as propranolol and testosterone, which are often used as highpermeability standards.
Metabolism of 8-PN in Caco-2 Monolayers
After 4 h of incubation of 8-PN with human intestinal Caco-2 cells, abundant phase II metabolites were detected on both the apical and basolateral sides of the monolayer. (The relative amounts of these metabolites on each side of the monolayer are discussed below.) The TEER levels after 4 h seemed to drop slightly to 482 T 35 WIcm 2 compared to the initial value of 554 T 12 WIcm 2 . Because both values remained well above 300 WIcm 2 , this indicated that the Caco-2 cell monolayers remained intact.
LCYMS chromatograms of the 8-PN conjugates in aliquots from the apical and basolateral sides of the Caco-2 cell monolayer are shown in Fig. 2 . Two glucuronide conjugates of 8-PN (G1 and G2) were detected eluting at 38 and 47 min, respectively. The exact mass measurements of the deprotonated molecules of these metabolites were m/z 515.1584 and 515.1587, which were within 5.9 and 6.5 ppm, respectively, of the theoretical molecular formula of C 26 H 27 O 11 for 8-PN monoglucuronide. Treatment of an aliquot of the Caco-2 cell incubation medium with bglucuronidase resulted in the disappearance of these peaks at 38 and 47 min, which also confirmed that metabolites G1 and G2 were glucuronides. Furthermore, the negative ion electrospray product ion tandem mass spectra of these metabolites (see Fig. 3A ) showed a loss of 176 mass units, which is characteristic of glucuronic acid, an ion of m/z 175 corresponding to deprotonated dehydrated glucuronic acid, and several low molecular mass fragment ions of m/z 113 and 85 corresponding to fragmentation of the glucuronic acid moiety. These data show that the metabolites eluting at 38 and 47 min were glucuronides of 8-PN. However, which peak corresponded to the 7-O-glucuronide or the 4 0 -O-glucuronide of 8-PN could not be determined from this information. Because the negative ion product ion mass spectra (see Fig. 3A ) provided no information regarding the position of glucuronidation, positive ion product ion mass spectra of the 8-PN glucuronides were obtained and are shown in Fig. 3B . Although the positive ion product ion tandem mass spectra of 8-PN glucuronides were dominated by the loss of glucuronic acid, a new type of fragment ion was observed at m/z 461, which corresponded to the neutral loss of C 4 H 8 from the prenyl group of 8-PN glucuronide. The composition of this neutral loss was confirmed by exact mass measurement. Because loss of C 4 H 8 produces a carbocation, this fragmentation pathway would be stabilized by an ortho hydroxyl group in the C-7 position of 8-PN. Therefore, G2 should correspond to 8-PN 4 0 -O-glucuronide because the ion of m/z 461 was more abundant in this positive ion electrospray product ion tandem mass spectrum than in that of G1 (Fig. 3B) . Yilmazer et al. 0 -hydroxyl groups are more acidic than the hydroxyl at the 5-position, these sites might be more susceptible to glucuronidation. In addition, the 5-hydroxyl group would be expected to hydrogen bond with the neighboring carbonyl group to form a six-member chelate, thereby reducing its reactivity toward nucleophilic substitution reactions such as glucuronidation. Similar glucuronidation patterns have been observed for other flavonoids such as chrysin where conjugation occurred only at hydroxyl group in position 7 but not at the hydroxyl group in position 5 (11) .
Using a similar approach, the metabolites S1 and S2, eluting at 62 and 67 min, respectively (see Fig. 4 ), were identified as 8-PN sulfates. The exact masses of the deprotonated molecules of these metabolites were m/z 419.0815 and 419.0820, respectively, which were within 3.4 and 4.6 ppm of the theoretical formula of 8-PN monosulfate, C 20 H 19 O 8 S. Treatment of an aliquot of the incubation medium with sulfatase resulted in the disappearance of these peaks (Fig. 4) . In addition, the negative ion product ion tandem mass spectra of the deprotonated molecules of these metabolites were dominated by a neutral loss of 80 mass units, which corresponds to the loss of a sulfate moiety (Fig. 4) . Unfortunately, informative positive ion electrospray tandem mass spectra of these sulfates could not be obtained due to the lack of formation of abundant protonated molecules. However, the same chemical processes that guided the formation of the 8-PN glucuronides should influence the formation of the 8-PN sulfates. Therefore, these two sulfate conjugates were probably 8-PN 4 0 -sulfate and 8-PN 7-sulfate. To investigate the possible involvement of an ABC transporter (anionic multidrug-resistance-associated protein, MRP family) on the efflux of 8-PN conjugates, the Caco-2 cell 4-h incubation experiment was repeated in the presence of MK571, which is a well-known inhibitor of ABCC2 (MRP2) (12) . Treatment of the Caco-2 cell monolayer with MK571 reduced the apical concentrations of the glucuronides G1 and G2 by 85 T 3 and 95 T 4%, respectively. This shows that an ABCC2 (MRP2) pump is probably involved in the efflux of 8-PN glucuronides toward the apical side of the Caco-2 cell monolayer. In contrast to the 8-PN glucuronides, concentrations of 8-PN sulfate conjugates were essentially unchanged after MK571 treatment. The concentration of 8-PN on each side of the Caco-2 cell monolayer was also unaffected by incubation with MK571.
Because no standards of 8-PN glucuronides or sulfates were available, the concentrations of these conjugates were estimated by using UV absorbance and 8-PN as the reference standard. The choice of 8-PN as a standard is supported by the observation that the UV spectra of 8-PN and its metabolites were identical (data not shown). UV measurements were carried out at 294 nm. After incubation of 50 mM 8-PN with a Caco-2 cell monolayer for 4 h, õ54% of the total dose was converted to glucuronides and õ3% to sulfates.
Metabolism of 8-PN by Human Hepatocytes
The total ion chromatogram and computer-reconstructed selected ion chromatograms for the negative ion electrospray LCYMS analysis of an aliquot from the incubation of 50 mM 8-PN with human hepatocytes are shown in Fig. 5 . The low intensity of the peak for 8-PN, eluting at 52 min in the total ion chromatogram shown in Fig. 5 , indicates that extensive metabolism occurred. Glucuronide conjugates were detected, but not sulfates, which contrasts with the Caco-2 cells that formed abundant sulfate metabolites. In addition, the 7-O-glucuronide (G1) of 8-PN was detected as an abundant deprotonated molecule of m/z 515 at a retention time of 38 min (Fig. 5) , whereas the 4 0 -O-glucuronide was not detected. The predominance of G1 formation over G2 in the hepatocyte incubation also differs from the Caco-2 cell incubations in which the 4 0 -O-glucuronide isomer (G2) was more abundant.
As many as six different glucuronide conjugates of 8-PN monooxidation products (G3YG8) were detected as their deprotonated molecules of m/z 531 (Fig. 5) . The two broad peaks eluting between 21 and 26 min in the mass chromatogram of m/z 531 probably each contained two or more unresolved isomers of 8-PN monooxygenated glucuronides. Two of these conjugates were identified as glucuronides of cis-and trans-8-PN alcohols (see structures in Fig. 1 ) based on the fact that after hydrolysis by b-glucuronidase, peaks corresponding to cis-and trans-8-PN alcohols were enhanced (data not shown). Attempts to identify the specific positions of glucuronidation using mass spectrometry were unsuccessful because in negative ion mode, these glucuronides fragmented almost exclusively to eliminate glucuronic acid without the formation of isomer-specific fragment ions (data not shown). Furthermore, no useful positive ion electrospray MSYMS product ion mass spectra were obtained for these glucuronides. Unambiguous identification of these isomers was also complicated by the fact that glucuronidation introduced an additional chiral center. Therefore, some of the resolved peaks might be glucuronide diastereoisomers.
Minor amounts of cis-and trans-8-PN alcohols were also detected in the incubation mixture eluting at 35Y36 min (see Fig. 5 ) as the only unconjugated metabolites of 8-PN. The structures of these alcohols were confirmed by comparison with an authentic standard of trans-8-PN alcohol and LCYMSYMS exact mass measurements as described elsewhere (9) . Following incubation of 8-PN with human hepatocytes, only õ4% was left unmetabolized after 4 h, and the 7-O-glucuronide of 8-PN (G1) accounted for õ80% of all metabolites (see Figs. 1 and 5 ).
Glucuronidation by cDNA-Expressed UDP-Glucuronyl Transferases
To determine which UGT isoforms might be responsible for glucuronidation of 8-PN, we carried out incubations with the cDNA-expressed isoforms of UDP-glucuronyl transferases UGT1A1, UGT1A6, UGT1A8, UGT1A9, UGT1A10, and UGT2B7. UGT1A1, UGT1A6, and UGT2B7 are expressed both in the liver and intestine, and UGT1A9 is expressed by the liver, kidney, and esophagus (13) . UGT1A8 and UGT1A10 are expressed specifically in intestinal tissue (14) . UGT1A1 was the most active isoform and catalyzed the glucuronidation of õ80% of 8-PN (see Table I ) (15) . The 7-O-glucuronide of 8-PN was the major metabolite followed by the 4 0 -O-glucuronide in a ratio of 98:2. UGT1A6, UGT1A8, and UGT1A9 displayed moderate activities ranging from 28% conversion for UGT1A9 to 14% for UGT1A6. The two isoforms with the lowest activity toward 8-PN were UGT2B7 and UGT1A10, catalyzing less than 2% conversion of 8-PN. Glucuronidation by various UDP-glucuronyl transferases was also regioselective. UGT1A6 and UGT2B7 preferentially conjugated 8-PN at the 4 0 -position, whereas the other isoforms preferentially attacked the 7-position.
DISCUSSION
Although in vitro assays indicated that 8-PN is only four to five times less estrogenic than estradiol, Milligan et al. (6) found that 1000-fold higher concentrations of 8-PN in drinking water were required for efficacy comparable to that of estradiol. These data suggest that the bioavailability of 8-PN is quite low in rats, but no quantitative data are available regarding the absorption of 8-PN in rats or other species. In preparation for clinical studies of hops extracts as alternatives to estrogen replacement therapy, we investigated the intestinal absorption and hepatic metabolism of the estrogenic hops compound 8-PN. To predict whether intestinal absorption, intestinal metabolism, or hepatic metabolism might limit the bioavailability of 8-PN in humans, we used the widely accepted Caco-2 cell model of human intestinal permeability. In addition, we used Caco-2 cells as a model for phase II intestinal conjugation reactions and human hepatocytes as a model for liver metabolism. Our data show that 8-PN exhibits good Caco-2 cell monolayer permeability, with an apparent permeability coefficient similar to well-absorbed drugs such as propranol. Because the P app values for 8-PN were essentially equal in both the apical-to-basolateral and basolateral-to-apical directions, there was no indication of efflux or active transport. Therefore, the mechanism of intestinal absorption of 8-PN is probably passive diffusion.
Although our data predict good intestinal absorption for 8-PN, these data also indicate that extensive phase II conjugation should occur during intestinal absorption. Approximately 50% of the 8-PN added to the incubation medium was converted to phase II conjugates by the human Caco-2 cell monolayers. This suggests that a large fraction of the 8-PN absorbed by the intestine will be conjugated to glucuronide and sulfate metabolites prior to reaching the liver. Although the Caco-2 cell model is recognized more as a model of human intestinal absorption than of phase II intestinal metabolism, there are many examples of conjugation reactions of xenobiotics by Caco-2 cells in the literature. For example, Caco-2 cell monolayers have been reported to form conjugates of dietary phenolic compounds such as chrysin (16) , genistein, apigenin (17) , and (j)epicatechin (18) . In addition, several pharmaceutical compounds have been shown to be metabolized by Caco-2 cells including L-amethyldopa (19) , apomorphine, dobutamine (20) , and various nonsteroidal anti-inflammatory drugs (21) . Furthermore, based on enzyme assays, Prueksaritanont et al. reported that Caco-2 cells express all conjugating activities except for the sulfation of acetaminophen (22) .
During incubation of 8-PN with Caco-2 cells, the phase II conjugates of 8-PN were concentrated on the apical side of the cell monolayer whether 8-PN was added initially to the apical side or to the basolateral side. These observations suggested the existence of an efflux mechanism that pumps these polar metabolites out of the cell in the apical direction. The protein responsible for the efflux of the 8-PN glucuronides G1 and G2 was identified as ABCC2 (MRP2) based on inhibition by MK571. It should be noted that no Caco-2 cytotoxicity was noted due to incubation with MK571 because the TEER values were unchanged compared to incubations that did not contain MK571. Furthermore, the concentrations of the sulfate conjugates on the apical and basolateral sides of the monolayer were unaffected by treatment with MK571. Previous studies on the metabolism of xenobiotics by Caco-2 cells determined the existence of a family of efflux proteins known as MRP (ATP binding cassette) that eliminates anionic metabolites such as glucuronides and sulfates (23) . One member of the family, ABCC2 (MRP2), is localized exclusively to the apical domain of polarized cells such as intestinal epithelial cells (24) . These characteristics of MRP are consistent with our results in which efflux of 8-PN glucuronides to the apical side of the Caco-2 cells was observed by ABCC2 (MRP2). It is interesting to note that the ABCC2 (MRP2) inhibitor MK571 did not affect the efflux of sulfates. This finding is consistent with observations of others that glucuronides and sulfates are substrates for separate transporters (23) .
The metabolic profiles of 8-PN obtained using human hepatocytes and the Caco-2 preparations were quite different. Whereas Caco-2 cells formed both glucuronides and sulfates, only glucuronides of 8-PN were observed in hepatocyte incubations. Furthermore, Caco-2 cells formed predominantly 4
0 -O-glucuronide and some 7-O-glucuronide, whereas hepatocytes formed almost exclusively the 7-Oglucuronide of 8-PN. These data indicate that there is differential expression between the human hepatocytes and Caco-2 cells of the UGT and sulfotransferase isoforms responsible for conjugation of 8-PN.
The results of the incubations with human hepatocytes suggest that 8-PN will exhibit high first-pass hepatic metabolism because only 4% of 8-PN remained unmetabolized after a 4-h incubation. The 7-O-glucuronide of 8-PN accounted for õ80% of the original dose, with the remainder being glucuronides of phase I metabolites, small amounts of unconjugated phase I products, and 4% unchanged 8-PN. Consistent with our previous studies of the metabolism of 8-PN by human liver microsomes, the 8-PN alcohols were the most abundant phase I metabolites in the hepatocyte incubation (9) . Like 8-PN, only a small fraction of these 8-PN alcohols were detected in their unconjugated form, which indicated a high efficiency of glucuronidation of these compounds. Because these in vitro experiments predict that extensive hepatic as well as intestinal metabolism of 8-PN should occur in vivo, only a minor fraction of orally administered 8-PN would be expected to reach the systemic circulation unchanged. This might explain the low in vivo efficacy of 8-PN in studies by Milligan et al. (6) . Our experiments with cDNA-expressed UGT isoforms provided additional insights into the metabolism of 8-PN. Among the isoforms tested, UGT1A1 showed the highest activity toward 8-PN and is probably primarily responsible for conjugation of 8-PN in vivo. In the liver, UGT1A1 is the primary enzyme responsible for conjugation of bilirubin and several clinically important drugs including irinotecan, buprenorphine, and ethinylestradiol. Interestingly, estradiol is also a substrate for UGT1A1. Therefore, the UGT1A1 active site might be highly complementary to the estrogen receptor ligand binding site. It would be interesting to determine whether other estrogens from botanical sources are metabolized by this isoform.
Another important characteristic of UGT1A1 is genetic variation of this isoform among individuals. Fisher et al. (25) examined glucuronidation rates for some UGT1A1-selective substrates in a bank of 20 livers and found that the rates of metabolism between individuals varied as much as 30-fold. Severely decreased expression of the UGT1A1 isoform, known as Gilbert's syndrome and characterized by asymptomatic unconjugated hyperbilirubinemia, occurs among 2Y19% of various populations (26) . These patients typically exhibit reduced clearance of the drugs that are primarily eliminated by glucuronidation. Our data suggest that the bioavailability of 8-PN would be much higher in individuals whose expression of UGT1A1 is impaired.
UGT1A1 has also been found in intestinal tissues (15) . Interestingly, this isoform was not detected in untreated Caco-2 cells but was found to be significantly induced by dietary flavonoids such as chrysin and quercetin (27, 28) . In addition, quercetin was found to induce UGT1A6 and the ABCC2 (MRP2) transporter (24) . Because quercetin and chrysin are abundant in the human diet, they would probably contribute to the up-regulation of UGT1A1 and UGT1A6 and reduce the bioavailability of 8-PN both via increased intestinal and hepatic glucuronidation. Other UGT-inducing compounds might be present in hops extracts as well. It is unknown at this time whether 8-PN itself induces any UGT isozymes.
UGT1A9 also exhibited moderate activity toward 8-PN. In addition to liver, this isoform is expressed in the kidney and esophagus. Expression in kidney is even more prevalent than in the liver; thus, this isoform might contribute significantly to the extrahepatic clearance of 8-PN. It is interesting to note that naringenin, a close analog of 8-PN, has also been shown to be a good substrate for UGT1A9 (14) . Among intestine-specific isoforms, only UGT1A8 showed activity toward 8-PN and was probably responsible primarily for the formation of 7-O-glucuronide in Caco-2 cells.
Overall, these data indicate that the formation of 4 0 -Oglucuronide in Caco-2 cells was probably catalyzed primarily by UGT1A6 and that UGT1A1 is another important isozyme responsible for the formation of most of the 8-PN 7-Oglucuronide in human hepatocytes. Because the UGT1A1 isoform is not expressed in untreated Caco-2 cells (15), formation of 7-O-glucuronide by this cell line was probably catalyzed by UGT1A8 and possibly UGT1A9, although expression of this isoform in Caco-2 cells is largely unknown. The relative contributions of other isoforms of UDP-glucuronyl transferases to the glucuronidation of 8-PN in Caco-2 cells are unknown at this time.
Although caution must be used when extrapolating Caco-2 data to humans, there are examples of such in vitro predictions that have been validated in vivo. In one example, studies of chrysin using Caco-2 and HepG2 cells predicted low and variable bioavailability due to extensive metabolism. In a subsequent phase I clinical study, Walle et al. (29) found that chrysin showed variable but poor bioavailability ranging from 0.003 to 0.8% of the administered dose. Walle et al. (29) concluded that aromatase inhibition by chrysin was negligible because pharmacologically relevant concentrations could not be achieved following oral administration. Similarly, we predict poor oral bioavailability and low estrogenicity in vivo for 8-PN due to extensive intestinal and hepatic metabolism catalyzed primarily by UGT1A1. In general, UGT1A1-mediated metabolic clearance is considered an undesirable characteristic of a potential drug candidate; as a result, UGT1A1 has been described as the BCYPD6 of phase II metabolism^ (25) . The role of inducible UGT1A1 in the conjugation of 8-PN might explain the anecdotal human reports of the estrogenicity of hops and the weak estrogenicity of hops in rats (6) . Phenotyping women for UGT1A1 activity in future clinical trials of hops estrogenicity might help explain response differences among the population. In addition, future studies should assess the potential for enterohepatic recirculation of 8-PN because this might be a mechanism for increasing serum levels of 8-PN during chronic administration. If enterohepatic recirculation occurs in humans, then pharmacologically effective concentrations of 8-PN might be achieved, which would need to be only in the nanomolar range.
Because dietary exposure to 8-PN occurs primarily through the consumption of beer, this should have little impact on human health given the low oral bioavailability of 8-PN predicted by our studies and the small amounts usually found in beer (30) . Of greater concern would be the consumption of dietary supplements containing hops extracts. Given the high estrogenicity of 8-PN in vitro, hops dietary supplements should be used in moderation until the human bioavailability and in vivo pharmacokinetics of 8-PN are fully resolved. Finally, the data presented in this paper should be useful for the design of future clinical trials of hops dietary supplements for safety and efficacy.
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